Biogen, Inc.

Biogen, Inc. is a Humankind 100 company whose ranking is based on its Humankind Value, a proprietary metric that provides an estimate of the overall dollar amount a company creates for investors, consumers, employees, and society at large.

Biogen, Inc. is a biotechnology company that specializes in treating neurological diseases. Through research, development, and distribution, this company helps people access treatments for disorders including Alzheimer’s, Multiple Sclerosis, and Spinal Muscular Atrophy.

Ticker: BIIB

Humankind Value: $139.3 B

Revenue: $12.4 B

Market Cap: $30.5 B

(All values are in US Dollars, where M=Million, B=Billion, T=Trillion.)

Biogen creates positive Humankind Value in large part due to its contributions to Healthcare R&D ($77.3 B), Pharmaceuticals ($51.9 B), and Economic Value ($5.1 B). The last 150 years of medical innovation have contributed to modern life expectancies, which is why Healthcare is important to our measure of Humankind Value. Biogen’s positive value from Healthcare R&D and Pharmaceuticals is linked to an estimated 2,681,089.8 additional years of life for people worldwide. The company adds economic value by offering to consumers goods and services that they value, paying employees for their labor in producing these goods and services, and providing value for shareholders. The Humankind Value of this company could improve, however, with reductions in Greenhouse Gases (-$951.5 M) and Air Pollution (-$200.6 M). Healthcare R&D, Pharmaceuticals, Economic Value, Greenhouse Gases, and Air Pollution are attached to this company as a result of its direct business activities. This company has a positive Humankind Value even when analyzed alone, and the consideration of supply chain interactions pushes its Humankind Value higher.

How the Humankind Value Methodology Drives the Rankings

We take a quantitative, data-driven approach to estimating the economic impact that companies have on investors, customers, employees, and society at large, rolling social responsibility into a single dollar value that we use to represent what a company is contributing to humanity. As far as we can tell, we're the first ones doing it this way.

LEARN MORE ABOUT OUR RESEARCH

ARTICLES

Institutional Investors Contact Us Customer Relationship Summary Terms of Use

A company’s Humankind Value is an estimate of how much value the company creates for humankind, is published annually, and is current as of April 29, 2022. It is based on a quantitative analysis that calculates the comprehensive economic value of a company based not only upon its financial performance metrics but also on the costs and benefits to society from conducting its business. This calculation also attempts to take into account the Humankind Value of the company’s critical supply chain partners. The components of the calculation include: (i) Investor Value, which is the estimated value to investors on the basis of multi-year profitability; (ii) Consumer Value, which is the estimated value to customers based on the offering of a product or service; (iii) Employee Value, which is the estimated value to employees based on their salaries, bonuses and benefits; and (iv) Societal Value, which is the estimated unaccounted costs and benefits to society from the operation of the company’s business.

Humankind Investments calculates a single dollar value of a company’s Humankind Value, which is intended to capture the aggregate worth of a company based upon its economic impact on humanity, defined as investors, customers, employees, and society at large. It’s important to understand that this single dollar value of Humankind Value for a company is not a precise measurement of the economic impact that companies have on humanity – rather, it represents a best faith estimate based on our internal model of how these companies behave and what the estimated impact on humanity of their behavior is. In other words, we’ve created a simplified mathematical representation of the real world, and are using that to derive this single dollar value for a company.

Humankind Investments believes that certain themes, including but not limited to hygienic products, industrial crop production, clean water, healthcare R&D, pharmaceuticals, medical devices, and medical services, all contribute to maintaining and extending human life. The Humankind Research Team works to estimate how many lives each of these themes, and other themes, are maintaining and lengthening, by synthesizing a broad range of independent data sources, such as nationally recognized data providers, scientific and academic papers, data gathered by government agencies, non-government organizations (NGOs), and other research entities, as well as financial statements and other public disclosures released by companies (10-K, 10-Q, presentations, conference calls), etc. Our researchers first estimate a human impact for a particular theme – estimates for the particular number of life-years added by the Humankind 100 companies are derived from proprietary Humankind Research Team work, described in the preceding sentence. Responsibility for the impact of that theme is then assigned to the companies that, according to the Humankind Research Team’s work, are contributing to the theme, either directly or indirectly. Our research process works to quantify the value of a human life and the value of a year of life well-lived based on economics research that aims to create an economic estimate of the value of a human life. This dollarization, or quantification, allows the impact of the themes we research to be compared in like-terms. Estimates for the number of life-years maintained and lengthened by the Humankind 100 companies for a particular theme are provided in the aggregate for each Humankind 100 company. We have provided examples of the estimates of the numbers of life-years maintained and lengthened for some, but not all, of the themes studied by our researchers. Other themes studied by our researchers can result in different estimates of life-years maintained and lengthened.

Market capitalization and revenue for the Humankind 100 companies are as of April 29, 2022, as reported by FactSet Research Systems Inc. Market capitalization for each Humankind 100 company reflects the total market value of the outstanding shares of each respective company. Revenue for each Humankind 100 company reflects the five-year average inflation-adjusted revenue for each respective company’s annual reporting period. Revenue for companies with less than five years of annual revenue are averaged over the respective company’s existing reported annual revenue periods.

This material is provided solely for informational and educational purposes. This information does not constitute an offer, recommendation, or solicitation to buy or sell any particular security or to adopt any specific investment strategy. The information herein has not been based on a consideration of any individual investor circumstance and is not investment advice, nor should it be construed in any way as tax, accounting, legal, or regulatory advice. Investors should seek independent legal and financial advice, including advice as to tax consequences, before making any investment decision. The information presented has been developed internally and/or obtained from sources believed to be reliable; however, Humankind Investments does not guarantee the accuracy, adequacy or completeness of such information. Past performance is not indicative of future results.

© Humankind Investments LLC 2022. See our Terms of Use for other important disclaimers and legal information.